藥碼
ALY01
藥名
Bevacizumab 25 mg/mL, 4 mL/Vial
英文商品名
化 臨採 Alymsys 針 100 mg/4 mL
中文商品名
艾麥思注射劑
螢幕名
化 臨採 Alymsys 針 100 mg/4 mL
劑型
Inj
規格
Inj. 100 mg/4ml/ vial
成分
藥理分類
Anticancer- Monoclonal antibodies
健保碼
KC01185219
ATC碼
適應症
| #高警訊藥品 |
Colorectal cancer(Metastatic): 轉移性大腸直腸癌
First- or second-line treatment in combination with (1) fluorouracil-based chemotherapy (2) fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy
Glioblastoma(Recurrent): 神經膠母細胞瘤
Ovarian (epithelial), fallopian tube, or primary peritoneal cancer: 卵巢上皮細胞、輸卵管或原發性腹膜癌
1. Stage III or IV disease: following initial surgical resection (in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab)
2. For patients who received no more than 2 prior chemotherapy regimens, in combination with (1) paclitaxel, doxorubicin [liposomal], or topotecan (2) carboplatin and paclitaxel or with carboplatin and gemcitabine
Non-small cell lung cancer, nonsquamous(NSCLC):非鱗狀非小細胞肺癌
First-line treatment in combination with carboplatin and paclitaxel
Cervical cancer(persistent/recurrent/metastatic): 子宮頸癌
In combination with paclitaxel and either cisplatin or topotecan
藥理
Vascular Endothelial Growth Factor (VEGF) Inhibitor, Monoclonal Antibody (Antineoplastic Agent)
Bevacizumab, a recombinant humanized monoclonal IgG1 antibody, binds to vascular endothelial growth factor (VEGF) and inhibits the interaction of VEGF to Flt1 and KDR receptors on the surface of endothelial cells. In the process, it prevents the proliferation of endothelial cells and formation of new blood vessels, thereby inhibiting tumour growth.
Bevacizumab, a recombinant humanized monoclonal IgG1 antibody, binds to vascular endothelial growth factor (VEGF) and inhibits the interaction of VEGF to Flt1 and KDR receptors on the surface of endothelial cells. In the process, it prevents the proliferation of endothelial cells and formation of new blood vessels, thereby inhibiting tumour growth.
藥動學
Volume of distribution: 2.66 L(female); 3.25 L(male)
Elimination half life: approximately 20 days (11-50 days)
Elimination half life: approximately 20 days (11-50 days)
禁忌症
1. Hypersensitivity to Avastin or any components of the product, Chinese hamster ovary cell products or other recombinant human or humanised antibodies
2. Patients with untreated Central Nervous System (CNS) metastases
3. Pregnancy
2. Patients with untreated Central Nervous System (CNS) metastases
3. Pregnancy
懷孕分類
C; limited information
哺乳分類
Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer does not recommend breastfeeding during treatment and for 6 months following the last dose of bevacizumab.
副作用
Common
asthenia, dizziness, headache, abdominal pain, constipation, loss of appetite, stomatitis, alopecia, hypertension and proteinuria(dose-dependent)
Serious
gastrointestinal perforations, hemorrhage, aterial thromboembolism
asthenia, dizziness, headache, abdominal pain, constipation, loss of appetite, stomatitis, alopecia, hypertension and proteinuria(dose-dependent)
Serious
gastrointestinal perforations, hemorrhage, aterial thromboembolism
劑量和給藥方法
Dosage:
1. Cervical cancer (persistent/recurrent/metastatic): 15 mg/kg every 3 weeks (with paclitaxel and either cisplatin or topotecan)
2. Colorectal cancer (metastatic): 5 mg/kg every 2 weeks (with bolus-IFL) or 10 mg/kg every 2 weeks (with FOLFOX4)
3. Glioblastoma (recurrent): 10 mg/kg every 2 weeks as a single agent
4. Hepatocellular carcinoma (unresectable/metastatic): 15 mg/kg once every 3 weeks (with atezolizumab on the same day)
5. NSCLC (nonsquamous, first-line therapy): 15 mg/kg every 3 weeks (with carboplatin and paclitaxel) for 6 cycles
6. Renal cell cancer (metastatic): 10 mg/kg every 2 weeks (with interferon alfa)
Administration:
1. The initial dose should be IV over 90 minutes, if the first infusion is well tolerated, the infusion time may be shorted to 60 minutes and then 30 minutes.
2. Withdraw the necessary amount of Avastin and dilute in a total volume of 100 ml of 0.9% NaCl.
1. Cervical cancer (persistent/recurrent/metastatic): 15 mg/kg every 3 weeks (with paclitaxel and either cisplatin or topotecan)
2. Colorectal cancer (metastatic): 5 mg/kg every 2 weeks (with bolus-IFL) or 10 mg/kg every 2 weeks (with FOLFOX4)
3. Glioblastoma (recurrent): 10 mg/kg every 2 weeks as a single agent
4. Hepatocellular carcinoma (unresectable/metastatic): 15 mg/kg once every 3 weeks (with atezolizumab on the same day)
5. NSCLC (nonsquamous, first-line therapy): 15 mg/kg every 3 weeks (with carboplatin and paclitaxel) for 6 cycles
6. Renal cell cancer (metastatic): 10 mg/kg every 2 weeks (with interferon alfa)
Administration:
1. The initial dose should be IV over 90 minutes, if the first infusion is well tolerated, the infusion time may be shorted to 60 minutes and then 30 minutes.
2. Withdraw the necessary amount of Avastin and dilute in a total volume of 100 ml of 0.9% NaCl.
小兒調整劑量
腎功能調整劑量
Prior to treatment:
There are no dosage adjustments provided in the manufacturer's labeling.
During treatment:
1. Nephrotic syndrome: Discontinue bevacizumab
2. Proteinuria ≥2 g/24 hours in the absence of nephrotic syndrome: Withhold bevacizumab until proteinuria <2 g/24 hours
There are no dosage adjustments provided in the manufacturer's labeling.
During treatment:
1. Nephrotic syndrome: Discontinue bevacizumab
2. Proteinuria ≥2 g/24 hours in the absence of nephrotic syndrome: Withhold bevacizumab until proteinuria <2 g/24 hours
肝功能調整劑量
There are no dosage adjustments provided in the manufacturer's labeling.
安定性
1. Store intact vials at 2°C to 8°C (36°F to 46°F); do not freeze.
2. Store in the original carton; protect from light. Do not shake.
2. Store in the original carton; protect from light. Do not shake.
注射給藥指引
給藥途徑
僅限靜脈輸注。不可透過靜脈推注或快速注射方式給藥。
For intravenous infusion only. Do not administer as an intravenous push or bolus.靜脈輸注液
應使用 0.9% 氯化鈉注射液 (生理食鹽水) 進行稀釋。請勿使用 5% 葡萄糖溶液 (D5W) 進行稀釋，因為其與藥品不相容。
Dilute using 0.9% Sodium Chloride Injection, USP. Do not use 5% dextrose solutions as每瓶稀釋液體積
抽取所需劑量的藥液後，將其加入 0.9% 氯化鈉注射液中，濃度應維持在 1.4-16.5?毫克/毫升的範圍內。由於藥瓶中不含防腐劑，抽取後剩餘的藥液應予以丟棄。
Withdraw the required amount of drug and dilute i注射濃度
給藥速率
首次輸注時間應為 90 分鐘。若患者對首次輸注耐受良好，第二次輸注時間可縮短至 60 分鐘。若第二次亦耐受良好，則後續所有輸注時間可固定為 30 分鐘。
The initial infusion should be administered over 90 minutes. If the first infusion is well-tolerated, the second infusion may be administered over 60 minutes. If well-tolerated, all subsequent infusions may be administered over 30 minutes.安定性
1. Store intact vials at 2°C to 8°C (36°F to 46°F); do not freeze.
2. Store in the original carton; protect from light. Do not shake.
2. Store in the original carton; protect from light. Do not shake.
注意事項
治療期間應監測胃腸穿孔、傷口癒合不良、出血、動脈血栓栓塞、高血壓及蛋白尿等風險。若發生嚴重輸注反應，應停止給藥並進行適當治療。
Monitor for gastrointestinal perforation, wound healing complications, hemorrhage, arterial thromboembolic events, hypertension, and proteinuria. Do not administer within 28 days prior to or after elective surgery. Discontinue treatment and provide medical management for severe infusion-related reactions.藥袋資訊
臨床用途
標靶治療藥物
主要副作用
胃腸穿孔、出血、高血壓、動脈血栓、影響傷口癒合、充血性心臟衰竭、嗜中性白血球減少
泡製方法
儲存方式
請置於 2-8℃ 冷藏儲存
注意事項
其他說明
化療藥局 化冰6 | 藥庫 化療
藥品外觀
顏色
形狀
剝痕
標記1
標記2
其他
健保藥價
4000
自費價
4800
仿單
資料庫
健保給付規定
## 資料使用與著作權聲明 本網站提供之藥品資訊，主要供醫療照護、藥事服務、衛教及一般資訊查詢使用。網站內容包含藥品名稱、成分、劑型、規格、適應症、使用方式、劑量、注意事項及其他相關資訊，實際內容依各藥品資料來源及本院資料建置情形而定。 一、醫療使用聲明 本網站所提供之藥品資訊僅供參考，不應單獨作為診斷、治療、處方調整、停藥或自行用藥之依據。 藥品之實際適應症、使用方法、使用劑量、使用頻率、療程及相關注意事項，應依個別病人之病情、年齡、肝腎功能、合併用藥及其他臨床狀況，由醫師或其他具資格之醫療專業人員進行專業判斷。 病人實際使用藥品時，請以醫師處方、藥袋標示及醫療專業人員之指示為依歸。請勿僅依本網站資訊自行增加、減少、停止或改變藥品使用方式及劑量。 如網站資訊與醫師處方、藥袋標示或醫療專業人員指示有所不同，應優先依醫師處方及醫療專業人員之個別指示使用。 二、資料來源與更新 本網站藥品資訊參考藥品資訊資料庫、主管機關核准之藥品仿單、藥品許可證資料、藥品製造或供應廠商提供之資料、本院藥品管理資料，以及其他經評估之專業資訊來源。 藥品資訊可能因主管機關核准內容、藥品許可證、仿單、供應狀況或臨床建議更新而有所變動，本網站將依實際作業情形進行維護與更新。 如需確認最新藥品核准資訊，應以主管機關公告、最新版藥品仿單及醫療專業人員判斷為準。 三、資料使用範圍 本網站內容可供個人查詢、醫療照護、衛教及非商業性學習使用。 使用者引用或轉載本網站內容時，應註明資料來源，並保留原有內容之完整性及必要之醫療警語，不得任意變更、變更原意或其他可能造成錯誤醫療理解之方式使用。 未經授權，不得將本網站內容大量重製、建立資料庫、進行商業性再利用，或以其他方式侵害相關著作權或其他權利。 四、著作權及第三方資料 本網站由本院自行製作之文字、編排、圖表、圖示及其他內容，其著作權或相關權利依著作權法及其他相關法令受到保護。 網站中引用之藥品仿單、藥品圖片、商標、產品名稱、主管機關資料或其他第三方資料，其著作權、商標權或其他相關權利仍歸原權利人所有。 本網站對第三方資料之使用，以醫療資訊提供、教育、研究或其他合法使用目的為原則，相關權利仍應依原資料來源及相關法令辦理。 五、責任範圍 本網站致力於維持資料之正確性與完整性，但藥品資訊可能隨核准事項、臨床資訊及供應狀況變更。 使用者因個別疾病、用藥或治療問題需要醫療判斷時，應洽詢醫師、藥師或其他適當之醫療專業人員。 本網站提供之一般性藥品資訊，無法取代醫療專業人員依個別病人狀況所作之醫療評估、處方及用藥指導。 六、聲明內容之調整 本院得依相關法令、資料來源、網站功能及實際作業需要，適時修訂本聲明內容。